Stay updated on Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Sign up to get notified when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.

Latest updates to the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page
- Check4 days agoChange DetectedUpdated from Revision: v3.0.1 to Revision: v3.0.2; the 'Back to Top' link was removed.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new medical terms related to renal cell carcinoma and pembrolizumab. However, many related topics and previous location details have been removed.SummaryDifference2%
- Check25 days agoChange DetectedThe web page has added information related to Kidney Cancer on MedlinePlus, enhancing its core content.SummaryDifference0.2%
- Check33 days agoChange DetectedThe page has been updated to version 2.16.12, and the topic of Kidney Cancer has been removed from the content.SummaryDifference0.2%
- Check40 days agoChange DetectedThe web page has been updated to include information on Kidney Cancer, and the version has been revised from v2.16.10 to v2.16.11.SummaryDifference0.2%
Stay in the know with updates to Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Stereotactic RT+Pembrolizumab in Oligometastatic Renal Cancer Clinical Trial page.